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sults of using the various estimation methods will be pre-
sented and discussed at the meeting.
CONCLUSIONS: Survival data from clinical trials are
normally not analyzed with the purpose of determining
average survival, but such estimates are necessary for
economic evaluation. Due to censoring, mean survival
can not be estimated without extrapolation or without
truncation in a restricted means analysis. The results in
terms of ICER will vary according to the estimation
method used. These variations should be examined in
sensitivity analyses
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OBJECTIVE: QuOLA-T was established as a real-life UK
outcomes audit to measure changes in Quality of Life (us-
ing the EORTC QLQ-C30 questionnaire) in patients with
metastatic breast cancer treated with docetaxel (Taxo-
tere®) outside the parameters of formal clinical trials.
METHODS: QuOLA-T is an ongoing programme in
which Quality of Life (QoL), clinical parameters of perfor-
mance status (Karnofsky Index) and response data are col-
lected at baseline and after every two cycles of treatment
and following chemotherapy. Demographic parameters
are also collected at baseline. Evaluable patients were de-
fined as those for whom a baseline registration and QoL
form have been received, details of chemotherapy are com-
pleted and at least one QoL form from the treatment phase
has been received. Non-evaluable patients were those still
receiving treatment and those not meeting the criteria
above. There were no significant differences between eval-
uable and non-evaluable patients in any of the parameters
at baseline, indicating that evaluable patients are a fair
representation of the entire data set.
RESULTS: The median number of cycles of Taxotere ad-
ministered: 5 (range 1–9). 103 patients completed planned
chemotherapy (49%), with a median of 6 cycles. Major
reason for withdrawal from treatment was progressive dis-
ease (25%), median number of cycles: 4. There were sig-
nificant detrimental intra-patient changes in two of the
QLQ-C30 domains (Fatigue and Diarrhea) but there were
significant beneficial intra-patient changes in four of the
domains (Emotional Functioning, Pain, Constipation and
Nausea and Vomiting).
CONCLUSIONS: This is the first large prospective Qual-
ity of Life monitoring programme conducted in an unse-
lected population of patients with metastatic breast cancer
using a recognized instrument. The hypothesis that quality
of life is significantly decreased during the active phase of
chemotherapy with Taxotere is not supported. This study
provides a much clearer picture of the real-life effects of
Taxotere on Quality of Life.
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OBJECTIVE: To investigate the effect of adjuvant breast
cancer therapy on quality of life, and to evaluate the oc-
currence of dose delay or reduction by type of therapy.
MATERIALS AND METHODS: The study population
was drawn from patients treated by a major oncology cen-
ter in Southern California. The inclusion criteria were: fe-
males 18 years old or older treated with adjuvant therapy,
with stage I, II or III non-metastatic breast cancer. Partici-
pants were sent up to five surveys: one before treatment ini-
tiation, two or three (depending on the number of cycles) at
regular intervals between treatments, and a final one 4
weeks after the end of the chemotherapy session. The survey
contained two quality of life instruments: the SF-36 and the
Breast Cancer Chemotherapy Questionnaire (BCQ).
RESULTS: At the beginning of the chemotherapy course,
40 patients were prescribed CMF (48.2%), 24 AC
(28.9%), 11 A-CMF sequential (13.3%), and 8 other regi-
mens (9.6%). Average values for the physical component
summary score (PCS) of the SF-36 did not vary over time,
ranging from 42.1 to 46.1. The mental component sum-
mary score (MCS) had a peak at mid-point (48.1), while it
stabilized to the initial value at the end of the therapy
(46.8 vs. 46.5). Comparisons of the difference between the
baseline quality of life scores and a summary measure of
the subsequent scores among treatment groups were not
significant. Correlation coefficients showed that, at each
period, MCS score was highly correlated with the disease-
specific BCQ score (correlation coefficients from 0.69 to
0.81, p  0.001). During the chemotherapy course, 32 pa-
tients experienced a dose delay, 12 a dose reduction and 9
prematurely terminated their chemotherapy regimen, with
no difference among treatment groups.
DISCUSSION: The MCS of the SF-36 was highly correlated
with the disease specific instrument, while the PCS was not.
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OBJECTIVES: To evaluate the quality of life (QL) in es-
sential hypertensives (EH) of Belarus, a European country
with a unique combination of the important rise in cardio-
vascular morbidity and mortality, highly restricted financ-
